Restless Legs Syndrome

Detailed Overview

RLS causes significant sleep disruption, leading to severe chronic daytime fatigue and impaired quality of life. The pathophysiology is heavily tied to central nervous system iron deficiency and dopaminergic dysfunction. RLS can be primary (idiopathic, often familial) or secondary to other conditions like end-stage renal disease (ESRD), pregnancy, or severe iron deficiency anemia. Over 80% of RLS patients also exhibit Periodic Limb Movements of Sleep (PLMS), consisting of involuntary leg twitching during non-REM sleep.

Epidemiology & Demographics

Prevalence is approximately 5-10% in North American and European adult populations. It is twice as common in women than in men. Onset can occur at any age, but severity usually increases with advancing age.

Etiological Mechanism

Primary RLS has a strong genetic component (autosomal dominant pattern in familial cases, involving variants in MEIS1 and BTBD9 genes). Secondary RLS is caused by states of systemic iron deficiency, uremia, or pregnancy (particularly the 3rd trimester).

Primary Causes

Central Iron Deficiency

Genetic Predisposition

Pregnancy

End-Stage Renal Disease (Uremia)

• Iron Deficiency Anemia: Low peripheral ferritin (<75 ng/mL) directly correlates with central iron depletion in the substantia nigra.
• Antidepressant Use: SSRIs, SNRIs, and mirtazapine can trigger or heavily exacerbate RLS symptoms.
• Pregnancy: Up to 25% of pregnant women develop RLS in the third trimester, resolving shortly after delivery.

The core pathology involves diminished iron stores in the brain, specifically within the substantia nigra and basal ganglia, despite normal peripheral serum iron in primary cases. Iron is a crucial co-factor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. This central iron deficiency leads to abnormal presynaptic dopamine transmission. Consequently, there is impaired descending dopaminergic inhibition of spinal sensorimotor pathways, resulting in hyper-excitability of the spinal cord that manifests as sensory discomfort and motor restlessness during periods of low sensory input (rest/night).

Characteristic Clinical Presentation

• Urge to Move Legs (Akathesia): An intense, deep-seated urge to move the legs, often described as "creeping, crawling, or pulling" deep inside the calves.
• Evening Exacerbation: Symptoms follow a strong circadian rhythm, peaking between 10 PM and 2 AM.
• Sleep Onset Insomnia: Severe difficulty falling asleep due to the need to walk or stretch the legs.

Physical Examination Signs

• Normal Neurological Exam
• Motor Restlessness

• Severe Chronic Insomnia: Leading to daytime cognitive impairment, extreme fatigue, and severe depression/anxiety.
• Augmentation: A paradoxical worsening of RLS symptoms (occurring earlier in the day, spreading to arms) caused by long-term dopaminergic drug use.

Diagnostic Criteria & Guidelines

Diagnosis is strictly clinical based on the 4 IRLSSG criteria: 1) Urge to move legs usually with dysesthesia; 2) Worsens with rest; 3) Relieved by movement; 4) Worsens in the evening/night. These must not be accounted for by another condition (mimics).

Differential Diagnosis

• Peripheral Neuropathy
• Nocturnal Leg Cramps
• Akathisia (Neuroleptic-induced)

Laboratory Tests & Biomarkers

• Serum Ferritin: Goal is > 75 ng/mL. Levels < 50-75 ng/mL mandate iron replacement in RLS.
• BUN and Creatinine: To evaluate for uremia/ESRD causing secondary RLS.

Imaging Modalities & Findings

• Transcranial Sonography:

• Intermittent RLS
  Symptoms occur < 2 times per week, treated symptomatically.
• Chronic Persistent RLS
  Symptoms occur >= 2 times per week causing major sleep disruption, requires daily therapy.

Second-Line & Adjunctive Therapy

Dopamine Agonists (Pramipexole 0.125-0.25 mg PO or Ropinirole 0.5-1 mg PO 2 hours prior to sleep). Used cautiously due to high risk of augmentation. For severe refractory cases: low-dose opioids (Methadone 5 mg PO) or IV iron formulations (Ferric carboxymaltose).

Surgical & Procedural Management

Not applicable for RLS.

Recommended Lifestyle Changes

• Abstain from caffeine, alcohol, and nicotine, especially in the afternoon/evening.
• Engage in moderate exercise, but avoid vigorous late-night workouts.
• Mental alerting activities (puzzles, video games) during rest can suppress symptoms temporarily.

Patient Counseling & Advice

Warn patients prescribed dopamine agonists about the risk of Impulse Control Disorders (gambling, hypersexuality) and Augmentation. Instruct them to take iron supplements on an empty stomach with orange juice for best absorption.

Follow-Up & Monitoring Schedule

Assess severity using the IRLS rating scale. Monitor serum ferritin every 3 months until > 75 ng/mL. Continually screen for signs of symptom augmentation if on dopaminergic agents.

Preventive Strategies

Maintaining adequate iron stores is the main preventative measure for individuals predisposed to RLS.

RLS is a lifelong condition that tends to progress slowly over decades. It does not lead to neurodegeneration (like Parkinson disease), but severely impacts quality of life if untreated.